All type of patients: 3 trials - APEX-AMI - COMMA - COMPLY
| pexelizumab vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious infection | 0.90 [0.64 1.26] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, | | All cause death | 0.94 [0.75 1.19] | p=1.00 | 0 | 7019 | 3 | APEX-AMI,COMMA,COMPLY, | | Major bleeding | 1.01 [0.53 1.91] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patient undergoing primary angioplasty: 1 trials - APEX-AMI
| pexelizumab vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious infection | 0.90 [0.64 1.26] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, | | All cause death | 1.04 [0.79 1.35] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, | | Major bleeding | 1.01 [0.53 1.91] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients undergoing primary angioplasty for AMI: 1 trials - APEX-AMI
| pexelizumab vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious infection | 0.90 [0.64 1.26] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, | | All cause death | 1.04 [0.79 1.35] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, | | Major bleeding | 1.01 [0.53 1.91] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
